NCT03588442 (PRECAR) is a clinical trial in Carcinoma, Hepatocellular, sponsored by Eastern Hepatobiliary Surgery Hospital.

Who is sponsoring NCT03588442?

NCT03588442 is sponsored by Eastern Hepatobiliary Surgery Hospital.

What condition does NCT03588442 study?

NCT03588442 studies Carcinoma, Hepatocellular.

Is NCT03588442 still recruiting?

NCT03588442 is currently status unknown. Last updated 22 May 2020.

Last reviewed 2020-05-22 · How we verify

NCT03588442: PRECAR

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prospective Surveillance for Very Early Hepatocellular Carcinoma

Status unknown Last updated 22 May 2020

What this trial tests

trial in Carcinoma, Hepatocellular in 10,000 participants. Status unknown.

Timeline

15 July 2018

Primary endpoint
15 July 2022

15 July 2023

Quick facts

Lead sponsor	Eastern Hepatobiliary Surgery Hospital
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	10,000
Start date	15 July 2018
Primary completion	15 July 2022
Estimated completion	15 July 2023
Sites	13 locations across China

Conditions studied

Carcinoma, Hepatocellular — all drugs for Carcinoma, Hepatocellular →

Sponsor

Eastern Hepatobiliary Surgery Hospital

Who can join

Adults 30 to 75, any sex, with Carcinoma, Hepatocellular. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Hepatocellular carcinoma is one the leading cause of increasing cancer-specific mortality worldwide. Early diagnosis of hepatocellular carcinoma provides opportunity for curative therapeutic approaches and relatively favorable prognosis. Herein, we intended to establish a biosignature for early diagnosis of hepatocellular carcinoma and stratification of risk population for intensive follow-up by implementing biannual follow-up investigation and collecting peripheral blood samples for screening.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Proteomics-driven noninvasive screening of circulating serum protein panels for the early diagnosis of hepatocellular carcinoma.
Xing X, Cai L, Ouyang J, Wang F, et al · · 2023 · cited 61× · PMID 38110372 · DOI 10.1038/s41467-023-44255-2
Cell-free DNA testing for early hepatocellular carcinoma surveillance.
Chen L, Wu T, Fan R, Qian YS, et al · · 2024 · cited 22× · PMID 38184937 · DOI 10.1016/j.ebiom.2023.104962
Early warning of hepatocellular carcinoma in cirrhotic patients by three-phase CT-based deep learning radiomics model: a retrospective, multicentre, cohort study.
Guo L, Hao X, Chen L, Qian Y, et al · · 2024 · cited 12× · PMID 39070173 · DOI 10.1016/j.eclinm.2024.102718
Current and emerging applications of liquid biopsy in pan-cancer.
Wang W, He Y, Yang F, Chen K. · · 2023 · cited 12× · PMID 37315508 · DOI 10.1016/j.tranon.2023.101720
Blood biomarkers of hepatocellular carcinoma: a critical review.
Zhao J, Hu Z, Zheng X, Lin Y, et al · · 2024 · cited 4× · PMID 39650722 · DOI 10.3389/fcell.2024.1489836
Hepatocellular Carcinoma Risk Stratification for Cirrhosis Patients: Integrating Radiomics and Deep Learning Computed Tomography Signatures of the Liver and Spleen into a Clinical Model.
Fan R, Shi YR, Chen L, Wang CX, et al · · 2025 · cited 1× · PMID 40951530 · DOI 10.14218/jcth.2025.00091

Verify or expand the search:

Other recruiting trials for Carcinoma, Hepatocellular

Currently open trials in the same condition.

NCT07010497 — A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Be · Phase 2 · recruiting
NCT07227012 — Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatmen · Phase 1, PHASE2 · recruiting
NCT06742892 — A Phase II Clinical Study to Evaluate HLX43 in Patients With Locally Advanced or Metastatic HCC Failed or Intolerance to · Phase 2 · recruiting
NCT06422403 — A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers · Phase 2 · recruiting
NCT06349980 — A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or W · Phase 2 · recruiting

Other Eastern Hepatobiliary Surgery Hospital trials

Trials by the same sponsor.

NCT07363356 — Drug Sensitivity Testing-Based Tumor Organoids to Guide Adjuvant Therapy After Hepatectomy for Primary Liver Cancer · Phase 2 · not yet recruiting
NCT07351513 — A Phase II Trial of Organoid Drug Sensitivity Testing to Guide Therapy in Unresectable Hepatocellular Carcinoma · Phase 2 · not yet recruiting
NCT07351591 — A Phase II Trial of Organoid Drug Sensitivity Testing to Guide Therapy in Unresectable Biliary Tract Cancers · Phase 2 · not yet recruiting
NCT07285850 — The Efficacy of Sequential Treatment With Bevacizumab Combined With Atezolizumab in Advanced Liver Cancer With MASLD · Phase 2, PHASE3 · recruiting
NCT06902389 — A Clinical Study of Multi-target Hi-TCR-T Cells in the Treatment of Advanced Hepatocellular Carcinoma · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03588442 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Eastern Hepatobiliary Surgery Hospital
Last refreshed: 22 May 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03588442.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing